We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

ATAI LIFE SCIENCES BV (ATAI) EUR0.10

Sell:$1.21 Buy:$1.26 Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$1.21
Buy:$1.26
Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$1.21
Buy:$1.26
Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.

Contact details

Address:
Wallstrasse 16
Berlin
10179
Germany
Telephone:
+49 (89) 21539035
Website:
https://atai.life/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ATAI
ISIN:
NL0015000DX5
Market cap:
$206.40 million
Shares in issue:
167.80 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
Netherlands
Currency:
US dollar
Indices:
n/a

Key personnel

  • Christian Angermayer
    Chairman of the Supervisory Board
  • Florian Brand
    Co-Chief Executive Officer
  • Srinivas Rao
    Co-Chief Executive Officer
  • Anne Johnson
    Chief Financial Officer
  • Sahil Kirpekar
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.